Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School describes…
Browsing: Multiple Myeloma
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School provides…
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School discusses…
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and…
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and…
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and…
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology and…
What is the Role of Maintenance Therapy and What do you do After
Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses Updates On The FORTE Trial: 3 Arm Study, Higher…
Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses Smoldering Myeloma ECOG Trial: Patients With Intermediate & High…
Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses IMWG Classification Of Smoldering Myeloma: Incorporates Earlier Features Of…
Jens Hillengass MD @JHillengass Of Roswell Park Comprehensive Cancer Center Discusses Updates In Myeloma: Bispecific Antibodies & New Treatment Coming…
Jens Hillengass MD @JHillengass Of Roswell Park Comprehensive Cancer Center Discusses B-Cell Maturation Antigen (BCMA): Many Trials Using This Marker…
Katja Weisel from University Medical Center Hamburg-Eppendorf discusses the role of daratumumab in first line treatment. Background: MM patients (pts)…
Katja Weisel from the University Medical Center Hamburg-Eppendorf discusses the efficacy and safety of daratumumab, bortezomib, and dexamethasone. Background: MM…
Earn CME: https://naccme.com/program/7329 In this presentation from the ‘Minimal Residual Disease (MRD) Testing in Multiple Myeloma’ symposium at the 2019…
Earn CME: https://naccme.com/program/7329 In this presentation from the ‘Minimal Residual Disease (MRD) Testing in Multiple Myeloma’ symposium at the 2019…
Jakob Lindberg CEO Of Oncopeptides Discusses Melflufen Study: Lengthy Time To Next Treatment, Significant Reduction In Bone Pain, Positive Feedback…
Jakob Lindberg CEO Of Oncopeptides Discusses How Is Melflufen Different: Its A Lipophilic Peptide-Conjugated Alkylator That Rapidly Delivers A Highly…
Philippe Moreau, MD Of Nantes Faculty of Medicine Discusses Daratumumab Phase 3 Study: Could Be A Pivotal Study In The…
Philippe Moreau, MD Of Nantes Faculty of Medicine Discusses Daratumumab Phase 3 Study: Phase 3 Randomized Study Of Daratumumab +…
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the…
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the…
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the…
Earn CME: https://naccme.com/program/7328 In this presentation from the ‘Updates on Treatment Approaches Across the Multiple Myeloma Spectrum’ symposium at the…
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-05 This on-demand webcast examines recent clinical trial data for novel and emerging therapies,…
Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate…
Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate…
Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate…
Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate…
Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate…
Amrita Krishnan, M.D. Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research Director, Multiple Myeloma Program Associate…
Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, More Trials & Drugs Coming In 2019. At…
Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, How MAIA & FORTE Trials Effect Clinicians. At…
Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, Highlights Of MAIA, FORTE & Tourmaline MM-3 Trials.…
Tianyi Tang, M.D. Hematology/Oncology Fellow At University of California, Irvine Discusses How The MAIA Trial Will Effect Clinicians . At…
Tianyi Tang, M.D. Hematology/Oncology Fellow At University of California, Irvine Discusses Highlights Of The MAIA Trial. At MOASC on Jan…
Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses…
Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, Discusses Clinical Data That Could Change…
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Current…
Rafael Fonseca, MD, Hematologist, Mayo Clinic, discusses Frontline MM Treatment Patterns. At The 60th ASH Annual Meeting on Dec 1,…
Rafael Fonseca, MD, Hematologist, Mayo Clinic, discusses TOURMALINE-MM3 Study In MM. At The 60th ASH Annual Meeting on Dec 1,…
Nikhil Munshi, MD, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine,…
Nikhil Munshi, MD, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine,…
Sundar Jagannath, MD, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, Discusses The Role Of Checkpoint…
Sundar Jagannath, MD, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses Proteasome Inhibitors In The…
Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses Outcomes Of The TOURMALINE-MM3 Study.…
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses The…
Andrzej Jakubowiak, MD, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, discusses Thoughts On The POLLUX &…
Andrzej Jakubowiak, MD, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, discusses ALCYONE Trial. At The 60th…
David Siegel, MD, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, discusses TOURMALINE-MM3 Study And The Treatment Of MM.…
Maria-Victoria Mateos, MD, Associate Professor of Medicine, University of Salamanca, discusses TOURMALINE-MM3 Study. At The 60th ASH Annual Meeting on…
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, discusses Anti-BCMA…
Maria-Victoria Mateos, MD, Associate Professor of Medicine, University of Salamanca, discusses Outcomes From The ALCYONE Study. At The 60th ASH…
David Siegel, MD, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, discusses Anti-BCMA CAR-T Cell Therapy For MM Patients.…
Rafael Fonseca, MD Hematologist, Mayo Clinic, discusses Effectiveness Of Anti-BCMA CAR-T Cell Therapy. At The 60th ASH Annual Meeting on…
Rafael Fonseca, MD Hematologist, Mayo Clinic, discusses Outcomes Of The POLLUX And CASTOR Studies. At The 60th ASH Annual Meeting…
Sundar Jagannath, MD Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses Outcomes Of CA204-142 In…
Peter Vorhees, MD Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses…
Nizar Bahlis, MD University of Calgary, Calgary, discusses The Future Of Anti-BCMA CAR-T Cell Therapy In MM. At The 60th…
Katja Weisel, MD Head of the Myeloma Center, University of Tubingen, discusses Current Maintenance Regimens In MM. At The 60th…
Maria-Victoria Mateos, MD Associate Professor of Medicine, University of Salamanca, discusses Addition Of Daratumumab To Revlimid/Dexamethasone In MM. At The…
Sen Zhuang, MD, PhD VP, Oncology Clinical Research, Janssen, discusses How LCAR-838M May Impact The Treatment Of MM. At The…
Edward Copelan, MD Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses The Role Of Allogeneic Transplantation…
Andrzej Jakubowiak, MD Professor of Medicine Director, Myeloma Program University of Chicago Medical Center, discusses GRIFFIN Study Outcomes. At The…
Habte Yimer, MD Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses Discussing The POLLUX And CASTOR Studies. At…
Habte Yimer, MD Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses The Future Of Anti-BCMA CAR-T Cell Therapy.…
Habte Yimer, MD Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses Outcomes Of The GRIFFIN Study. At The…
Maria-Victoria Mateos, MD Associate Professor of Medicine, University of Salamanca, discusses Discussing The CASTOR Trial Presented At ASH 2018. At…
Sundar Jagannath, MD Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses Maintenance Regimens For Multiple…
Robert Rifkin, MD Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers Discusses Does Anti-BCMA CAR-T Cell Therapy…
Andrew Pecora, MD Chief Innovation Officer, Professor and Vice President of Cancer Services John Theurer Cancer Center Discusses The Necessity…
David Siegel, MD Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center Discusses Results Of MM014 Study. At The 60th…
Andrzej Jakubowiak, MD, PhD Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center discusses Multiple Myeloma Maintenance Regimens.…
Nikhil Munshi, MD Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine,…
Rafael Fonseca, MD Hematologist, Mayo Clinic Discusses Maintenance Regimens For MM At The 60th ASH Annual Meeting on Dec 1,…
Peter Vorhees, MD Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute Discusses…
Habte Yimer, MD, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology Discusses Lyra Trial In Newly Diagnosed MM At…
Sen Zhuang, MD, PhD, VP, Oncology Clinical Research, Janssen, Discusses LCAR-838M Study In Relapsed/Refractory MM At The 60th ASH Annual…
Rod A. Humerickhouse, M.D., PhD Group Project Leader, Oncology Development, AbbVie Discusses Venetoclax In Treatment Of MM At The 60th…
Nizar Bahlis, M.D. University of Calgary, Calgary Discusses ASH 2018: CASTOR & POLLUX Studies Impact At The 60th ASH Annual…
Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses Whats On The Horizon For Myeloma at Lymphoma…
Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses Triplet Drug Combo at Lymphoma & Myeloma on…
Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses The Role Of Ixazomib In Front Line Therapy…
Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses Renal Insufficiency At Time Of Diagnosis at Lymphoma…
Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses MRD Not Ready Outside Clinicial Trials at Lymphoma…
Adriana Rossi, M.D. Associate Clinical Director Myeloma Center Weill Cornell Medicine Discusses Front Line Therapy Of Myeloma at Lymphoma &…
Joseph Mikhael, M.D. Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen)…
Joseph Mikhael, M.D. Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen)…
Joseph Mikhael, M.D. Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen)…
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer…
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer…
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer…
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer…
C. Ola Landgren, M.D. Chief of the Myeloma Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer…
Samir Parekh, M.D. Associate Professor of medicine, hematology, medical oncology, and oncological sciences at the Icahn School of Medicine at…
Suzanne Lentzsch, M.D., PhD Associate Professor of Medicine & Director of the Multiple Myeloma and Amyloidosis Service at Columbia University…
Shaji Kumar, M.D. Professor of Medicine Mayo Clinic College of Medicine In Rochester, Minnesota Discusses Allogeneic Stem Cell Transplant: Multiple…
Habte Yimer, M.D. Chairman, Hematology/Oncology Department, CHRISTUS Trinity Mother Frances Hospital, Medical Oncology Specialist in Tyler, TX Discusses Where Does…
Habte Yimer, M.D. Chairman, Hematology/Oncology Department, CHRISTUS Trinity Mother Frances Hospital, Medical Oncology Specialist in Tyler, TX Discusses Lyra: Front…
Sarah Lee, M.D. Hematology/Oncology Fellow at Cleveland Clinic Discusses The Future Of Daratumumab At The 60th ASH Annual Meeting on…
Sarah Lee, M.D. Hematology/Oncology Fellow at Cleveland Clinic Discusses Daratumumab In A Primary Fractory Population At The 60th ASH Annual…
Rafael Fonseca, M.D. Clinical Investigator For The Damon Runyon Cancer Research Fund Discusses MAIA Study, AMG 420 Compound, KRD Transplant…
Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch…
Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch…
Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch…
Sundar Jagannath, M.D. Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch…
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Whats Next For Isatuximab At The 60th ASH Annual Meeting on…
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Value Of Dexamethasone At The 60th ASH Annual Meeting on Dec…
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses Phase 2 Study Isatuximab & Dexamethasone At The 60th ASH Annual…
Joanne Lager, M.D. Head of Oncology Development, Sanofi Discusses ISA Combo: Velcade, Revlimid & Dexamethasone At The 60th ASH Annual…
Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses the next steps for Ixazomib in Multiple Myeloma after…
Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses Duration of Maintenance and the Advantage to High Risk…
Francesca Gay, MD, PhD of the GIMEMA, European Myeloma Network discusses the results of the phase 3 study TOURMALINE-MM3. The…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ajai Chari, M.D. Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate…
Ken Anderson M.D., Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute…
Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr.…
Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr.…
Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr.…
Earn CME: https://naccme.com/program/7313 In this presentation from the ‘New Horizons in the Treatment of Relapsed and Refractory Myeloma symposium, Dr.…
Earn CME: https://naccme.com/program/7312 In this presentation from the ‘Looking for One in a Million: Is MRD the New Primary Goal…
Earn CME: https://naccme.com/program/7312 In this presentation from the ‘Looking for One in a Million: Is MRD the New Primary Goal…
In this weeks video, Dr. Brian G.M. Durie talks about ways myeloma patients, caregivers, or family members can give back…
In this weeks video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and…
In this weeks video, Dr. Brian G.M. Durie discusses the Black Swan Research Initiatives 3 Cure trials, which use new…
In this weeks video, Dr. Brian G.M. Durie details the results of the STORM 2b trial, which uses selinexor in…
In this weeks video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma…
In this weeks video, Dr. Brian G.M. Durie comments on why it is not necessary for multiple myeloma patients to…
In this video, Dr. Brian G.M. Durie explains how researchers are studying minimal residual disease (MRD) testing further to better…
In this video, Dr. Brian G.M. Durie explains that active myeloma is diagnosed if a patient has CRAB features and…
Earn CME: https://naccme.com/program/7307 In this Key Insights activity, Drs. Morton Coleman and Ruben Niesvizky discuss myeloma presentation highlights from Lymphoma…
Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the current outlook of Waldenströms macroglobulinemia (WM), from…
Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, updates us at the European…
Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, presents exciting results from clinical…
Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, discusses the updated analysis of the CASTOR trial (NCT02136134)…
Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Jesús San…
Heinz Ludwig, MD, PhD, from Wilhelminen Cancer Research Institute, Vienna, Austria, discusses treatment sequencing in multiple myeloma (MM). Dr Ludwig…
Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Evangelos Terpos,…
Functional imaging techniques serve an essential role in diagnostics. Here, Elena Zamagni, MD, PhD, of the University of Bologna, Bologna,…
Annemiek Broyl, MD, PhD, from Erasmus Medical Center and University, Rotterdam, Netherlands, discusses how to treat high-risk multiple myeloma (MM).…
Alessandra Larocca, MD, PhD, of the University Hospital Città della Salute e della Scienza, Torino, Italy, discusses the importance of…
The mechanism for the previously unknown occurrence of thrombocytopenia and neutropenia in patients with myeloma treated with immunomodulatory drugs (IMiDs)…
Dr Suzanne Lentzsch, MD, PhD, of Columbia University, New York, NY, presents data from the latest clinical trials testing drugs…
Somatic mutations can be used to inform diagnosis and prognosis, but they are also useful targets for novel therapies. Valeria…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Meletios Dimopoulos, MD, of the University…
Meletios Dimopoulos, MD, of the University of Athens School of Medicine, Athens, Greece, gives an overview of the OPTIMISMM trial…
In this interview, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Meletios Dimopoulos, MD,…
BCMA is an exciting therapeutic target for multiple myeloma (MM). Here, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester,…
Multiple myeloma (MM) is at the forefront of immunotherapeutic developments, including T-cell therapies and bispecific antibodies. Here, our expert panel…
Understanding the mechanisms of drug resistance in multiple myeloma (MM) is vital in order to improve treatment. In this comprehensive…
Ivan Borrello, MD, of Johns Hopkins University School of Medicine, Baltimore, MD, discusses the role of the microenvironment in multiple…
Is measurable residual disease (MRD) ready for prime time in multiple myeloma (MM)? Gareth Morgan, MD, PhD, FRCP, FRCPath, of…
Keith Stewart, MB, ChB, of the Mayo Clinic, Rochester, MN, rounds up the Myeloma 2018 meeting, held in San Diego,…
The experts at the Myeloma 2018 meeting in San Diego, CA, discussed the successes, challenges and future outlook for CAR…
From the Myeloma 2018 meeting, held in San Diego, CA, the experts discuss novel targets in multiple myeloma (MM), including…
The progression to multiple myeloma (MM) in patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)…
In this exciting discussion, the experts explore the prevocative question of ‘is precision medicine a bust in multiple myeloma?’ Topics…
From the Myeloma 2018 meeting, held in San Diego, CA, Gareth Morgan, MD, PhD, FRCP, FRCPath, of UAMS Myeloma Institute,…
Keith Stewart, MB, ChB from the Mayo Clinic, Rochester, MN, is joined by Kenneth Anderson, MD, of the Dana-Farber Cancer…
CAR T-cells are an exciting new therapeutic area in multiple myeloma (MM). Here, the experts discuss the current landscape of…
CRISPR technology is being used to define mechanisms of multiple myeloma (MM) drug resistance. Here, Constantine Mitsiades, MD, PhD, of…
John P. Fruehauf, MD, UC Irvine Health, Looks at Data from Combination Studies | ASCO 2019 Will Show The Role…
John P. Fruehauf, MD, UC Irvine Health, explains New Treatment for Melanoma is Working Everywhere | Working For Metastatic Disease…
John P. Fruehauf, MD, UC Irvine Health, Looks at Combinations of Therapies | Combine Targeted BRAF Agents with Immunotherapy at…
John P. Fruehauf, MD, UC Irvine Health, explains Practice-Changing Impact of Presented Data | Durability to the Benefit of Immunotherapy…
John P. Fruehauf, MD, UC Irvine Health, explains What to do with Stage 3 Disease | Which is a Better…
John P. Fruehauf, MD, UC Irvine Health, explains how 50% of Melanoma Patients Develop Brain Metastases | BRAF-MEK & Immunotherapy…
John P. Fruehauf, MD, UC Irvine Health, explains New Agents for BRAF-MEK Inhibition | Binimetinib/Encorafenib at MOASC 2018
John P. Fruehauf, MD, UC Irvine Health, explains KEYTRUDA & Role in Stage 4 Melanoma | Immunotherapy has Long-Term Benefits…
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting novel avenues for multiple myeloma (MM) therapy from…
Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses new strategies for clinical trial design in multiple…
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses considerations in the treatment of high risk multiple myeloma…
Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses two Phase III multiple myeloma (MM) transplantation studies…
Monika Engelhardt, MD, of the University Medical Center Freiburg, Freiburg, Germany, speaking from the 1st European Myeloma Network (EMN) Meeting…
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses advances in the classification of high risk multiple myeloma…
Speaking from the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden, Dr Jesús…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the…
In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses how measurable residual disease (MRD) should be…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the…
The treatment of multiple myeloma (MM) can be very costly. Speaking from the American Society of Oncology (ASCO) 2018 Annual…
Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the situations in which measurable residual disease (MRD) should and…
John P. Fruehauf, MD, UC Irvine Health, Axillary Dissection in Stage 2 or 3 Melanoma | No Benefit from Taking…
Nicola Giuliani, MD, PhD, from the University of Parma, Parma, Italy, talks about the clinical approach required when identifying and…
Speaking at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, Nicola Giuliani, MD, PhD, from the University…
Paul Richardson, MD, from Dana-Farber Cancer Institute, Boston, MA, discusses the exciting results of the Phase III OPTIMISMM trial (NCT01734928)…
The CRB-401 trial (NCT02658929) aims to investigate the efficacy of bb2121 for multiple myeloma (MM) patients. In this interview, recorded…
Measurable residual disease (MRD) analysis is becoming increasingly commonplace as a prognostic indicator and tool for guiding the management of…
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, presented results from the CRB-401 trial (NCT02658929) at the 23rd…
Lenalidomide is widely used for multiple myeloma (MM); however, while it is effective, most patients relapse and become lenalidomide-refractory. In…
Understanding the mutations and whole-genome interactions taking place in multiple myeloma (MM) is crucial for disease understanding and therapy research.…
Shaji Kumar, MD, of the Mayo Clinic, Rochester, MN, presents the results of some preclinical and clinical trials investigating the…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Paul Richardson, MD, of…
The response of patients with multiple myeloma (MM) to therapy is always variable. Speaking from the 23rd Congress of the…
Defibrotide has previously been studied in post-stem cell transplant patients with veno-occlusive disease with a suitable investigational new drug (IND).…
Many tumor cells are able to evade apoptosis, with the potential to survive in the body indefinitely. Here, Shaji Kumar,…
The HORIZON study (NCT02963493) aims to determine the efficacy of melflufen in combination with dexamethasone in relapsed/refractory multiple myeloma (MM).…
In this weeks video, Dr. Brian G.M. Durie explains how the ARROW study demonstrated efficacy and low toxicity for weekly…
In this video, Dr. Brian G.M. Durie explains how high-dose melphalan therapy that precedes an ASCT may cause some side…
In this video, Dr. Brian G.M. Durie explains which lifestyle choices can improve myeloma patients outcomes. BOTTOM LINE: Live as…
In this video, Dr. Brian G.M. Durie explains why MRD-negative status and MRD-positive status are not clear indicators for next…
In this weeks video, Dr. Brian G.M. Durie recommends ways myeloma patients can avoid infections, such as using preventative antibiotics,…
In this weeks video, Dr. Brian G.M. Durie discusses the ways patients can learn from one another at IMF-affiliated support…
Drug development for multiple myeloma (MM) has recently reached such heights that there is now a plethora of novel inhibitors…
In this weeks video, Dr. Brian G.M. Durie provides helpful hints for myeloma patients to follow healthful diets. The BOTTOM…
In this weeks video, Dr. Brian G.M. Durie explains why a Freelite test may be inaccurate. BOTTOM LINE: Discuss abnormal…
The use of checkpoint inhibitors in multiple myeloma (MM) is an exciting area. The data from two KEYNOTE studies examining…
Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, gives an overview of his top 5 abstract presentations at the…
Multiple myeloma (MM) updates in the relapsed/refractory setting at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago,…
CAR T-cells are an exciting therapeutic avenue for multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General Hospital Cancer…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stephan Grupp, MD, PhD, of…
A number of novel treatment strategies for multiple myeloma (MM) are being studied. A few such studies are discussed here…
Multiple myeloma (MM) is an expensive cancer to treat, with costly drugs that are often used in combination. In this…
The anti-BCMA CAR T-cell therapy bb2121 looks extremely promising in multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General…
IV administration of daratumumab has several issues, including a long infusion time (~7 h) and the likelihood of infusion-related toxicities.…
Ajai Chari, MD, PhD, of Mount Sinai School of Medicine, New York, NY, presented data from the recent Phase Ib…
Francesca Gay, MD, of the University of Torino, Torino, Italy, provides an efficacy data update from the FORTE trial (NCT02203643),…
While there are many clinical trials exploring the effect of various novel agents in combination with lenalidomide-dexamethasone therapy in multiple…
Prof Wee Joo Chng, MD discusses the importance of Minimal Residual Disease (MRD) testing in Multiple Myeloma
Kinase inhibitors are one of the most successful forms of therapy for hematological malignancies, with further potential due to new…
The contemporary viewpoint is that multiple myeloma (MM) is a group of separate diseases, rather than just one type of…
Monika Engelhardt, MD, of the University Medical Center Freiburg, Freiburg, Germany, discusses a promising study conducted at her center using…
In this video, Fabio Malavasi, MD, of the University of Turin, Turin, Italy, discusses immunotherapy in multiple myeloma (MM) from…
Despite recent advances in drug development, autologous stem cell transplant (ASCT) is still, to date, the most effective treatment for…
Abstracts are often the most informative parts of scientific publications, as they contain a complete overview of the entire paper.…
While daratumumab is one of the most effective treatments for multiple myeloma (MM), ~50% of all patients who the drug…
Autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients has often been capped at 65 years of age. However,…
Autologous stem cell transplantation is here to stay for multiple myeloma (MM). However, once a treatment has been developed, there…
Measurable residual disease (MRD) status is a valuable prognostic marker in multiple myeloma (MM), but questions still remain. Speaking from…
Measurable residual disease (MRD) is evaluated and analyzed in clinical trials, but less attention is currently given to it in…
Elderly patients with multiple myeloma (MM) are often denied intensive treatment due to the fear they will not be able…
Measurable residual disease (MRD) can be determined using a variety of techniques. However, the majority of trials perform bone marrow…
While it is understandable that elderly patients with multiple myeloma (MM) are generally excluded from more aggressive treatments, Mohamad Mohty,…
Noa Biran, MD, discusses her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients at…
Noa Biran, MD, talks about her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients…
Noa Biran, MD, talks about her thoughts on the logistics involved in delivering CAR-T in the BB2121 study in multiple…
There are many questions surrounding minimal residual disease (MRD) detection and its role in decision making; for example, whether drug…
Ola Landgren, MD, PhD, from Memorial Sloan Kettering Cancer Center, NY, describes novel uses for minimal residual disease (MRD) measurement…
Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses an exciting preclinical investigation of the…
Treatments for multiple myeloma (MM) in newly diagnosed and relapsed patients differ between regions, particularly with the rapid advancements in…
Previous clinical trial investigations have established that daratumumab plus bortezomib, melphalan and prednisone, also known as dara+VMP, is significantly more…
The 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, presented exciting data from multiple myeloma…
A small proportion (~20%) of multiple myeloma (MM) patients are at a high risk of relapse and aggressive disease progression.…
Daratumumab is one of the most promising new therapies in multiple myeloma (MM). Here, Matthew Jenner, MBBS, MRCP, FRCPath, PhD,…
Lenalidomide monotherapy has proven to be an effective maintenance treatment for multiple myeloma (MM). Matthew Jenner, MBBS, MRCP, FRCPath, PhD,…
Noa Biran, MD, discusses the impact of the BB2121 study in multiple myeloma patients and how the results compare to…